Destiny Pharma Says New Guidelines Prove Lead Product Marketability
Destiny Pharma Says New Guidelines Prove Lead Product Marketability
Read moreFri, 25th Jan 2019 10:58
Destiny Pharma Says New Guidelines Prove Lead Product Marketability
Read moreDestiny Pharma Appoints Former Polyphor Medical Chief To Board
Read more(Sharecast News) - Clinical stage biotechnology company Destiny Pharma reported on the publication of results from a positive phase 1 clinical study in 60 healthy United States volunteers using a nasal gel formulation of its lead drug, XF-73 (exeporfinium chloride), on Wednesday.
Read moreDestiny Pharma's XF-73 Associated With Reduced Staphylococcus Aureus
Read moreDestiny Pharma Says Non-Executive Joe Eagle Steps Down From Board
Read moreDestiny Pharma Interim Loss Narrows On Smaller Share Option Charge
Read more(Alliance News) - Destiny Pharma PLC on Tuesday said it has been awarded a grant along with the University of Sheffield for their research collaboration on drug-resistant infections.Shares
Read moreLONDON (Alliance News) - Destiny Pharma PLC on Tuesday reported a significantly widened annual loss as expenses surged in the run-up to the development of its lead candidate.For 2018, the a
Read more(Sharecast News) - Destiny Pharma on Tuesday reported a wider annual loss as it increased research and development costs, although the company is "well funded" through to the second half of next year.
Read moreWednesday 3 April AAFull Year ResultsCMC MarketsTrading GroupTrading Year Year 4
Read moreLONDON (Alliance News) - Destiny Pharma PLC on Wednesday said it has partnered with MedPharm to develop new formulations of its XF-platform compounds.MedPharm is a contract provider of and
Read moreLONDON (Alliance News) - Destiny Pharma PLC on Monday reported positive results in a second phase 1 clinical study examining the anti-irritation features of its XF-73 nasal gel.The study, a
Read more(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive data and the non-irritant classification for its XF-73 nasal gel on Monday.
Read moreLONDON (Alliance News) - Destiny Pharma PLC said Friday that it has secured a GBP1.6 million grant for examining novel drugs to prevent, control and eradicate life threatening bacteria or without
Read more